Abstract: Provided are compositions, devices and systems, methods for assessing, treating and/or preventing an intraocular disease or disorder in a subject, wherein the etiology of the intraocular disease or disorder comprises infection of a microorganism in the intraocular space or cavity of the subject. Provided are compositions, devices and systems, and methods for assessing, treating and/or preventing age-related macular degeneration (AMD) in a subject, e.g., a human patient.

Abstract: A multi-channel parallel optical communication module includes a casing having an airtight cavity, an optical communication assembly accommodated in the airtight cavity, and a temperature controller in thermal contact with the optical communication assembly. The optical communication assembly includes a plurality of optical communication units disposed at same level, and a number of the plurality of optical communication units is greater than four.

Abstract: The invention provides cell culture compositions for regulatory T-cells that include particular synthetic peptides. Also provided are methods of treating autoimmune diseases such as age-related macular degeneration and uveitis with regulatory T-cells prepared using said compositions.

Abstract: Features related to systems and methods for automated generation of a machine learning model based in part on a pretrained model are described. The pretrained model is used as a starting point to augment and retrain according to client specifications. The identification of an appropriate pretrained model is based on the client specifications such as model inputs, model outputs, and similarities between the data used to train the models.

Abstract: The present invention relates to a salt of (6-(4-((4-(1H-pyrazol-4-yl)phenypamino)pyrimidin-2 -yl)-1-methyl-1H-indo1-2-yl)(3,3-difluoroazetidine-1-yl)methanone (hereinafter referred to as “compound A”), a solid form of the salt, a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and uses of the solid form as a Rho-associated protein kinase (ROCK) inhibitor, preferably a selective ROCK2 inhibitor.

Abstract: A preparation method for a novel Rho-related protein kinase inhibitor having the structure of formula A and an intermediate in the preparation method.

Abstract: Techniques are described automatically determining runtime configurations used to execute recurrent neural networks (RNNs) for training or inference. One such configuration involves determining whether to execute an RNN in a looped, or “rolled,” execution pattern or in a non-looped, or “unrolled,” execution pattern. Execution of an RNN using a rolled execution pattern generally consumes less memory resources than execution using an unrolled execution pattern, whereas execution of an RNN using an unrolled execution pattern typically executes faster. The configuration choice thus involves a time-memory tradeoff that can significantly affect the performance of the RNN execution. This determination is made automatically by a machine learning (ML) runtime by analyzing various factors such as, for example, a type of RNN being executed, the network structure of the RNN, characteristics of the input data to the RNN, an amount of computing resources available, and so forth.

Abstract: Features related to systems and methods for automated generation of a machine learning model based in part on a pretrained model are described. The pretrained model is used as a starting point to augment and retrain according to client specifications. The identification of an appropriate pretrained model is based on the client specifications such as model inputs, model outputs, and similarities between the data used to train the models.

Abstract: Provided are compositions, devices and systems, methods for assessing, treating and/or preventing an intraocular disease or disorder in a subject, wherein the etiology of the intraocular disease or disorder comprises infection of a microorganism in the intraocular space or cavity of the subject. Provided are compositions, devices and systems, and methods for assessing, treating and/or preventing age-related macular degeneration (AMD) in a subject, e.g., a human patient.

Abstract: In some examples, a flat Bottom Shadow Ring (fBSR) is provided for processing a substrate in a processing chamber. An example fBSR comprises an overhang for covering an edge of the substrate in the processing chamber. The overhang includes a fiat zone that extends radially outward over the outer edge of the substrate.

Abstract: A multi-channel wavelength division multiplexing light emitting device includes a casing and an optical communication assembly accommodated in the casing. The optical communication assembly includes a substrate, a plurality of first light emitting units disposed on the substrate, a plurality of second light emitting units disposed on the substrate, a first wavelength division multiplexer, and a second wavelength division multiplexer. The first light emitting units are arranged to correspond with the first wavelength division multiplexer. The second light emitting units are arranged to correspond with the second wavelength division multiplexer.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive one or more of an indication of a set of timing offset values associated with a hybrid automatic repeat request acknowledgment (HARQ-ACK) codebook or information associated with a set of start and length indicator values (SLIVs) for candidate data channels associated with the HARQ-ACK codebook. The UE may transmit the HARQ-ACK codebook, the HARQ-ACK codebook being based at least in part on one or more of distinct values of the set of timing offset values or distinct values of the set of SLIVs. Numerous other aspects are described.

Abstract: A multi-channel wavelength division multiplexing light emitting device includes a casing and an optical communication assembly accommodated in the casing. The optical communication assembly includes a substrate, a plurality of first light emitting units disposed on the substrate, a plurality of second light emitting units disposed on the substrate, a first wavelength division multiplexer, and a second wavelength division multiplexer. The first light emitting units are arranged to correspond with the first wavelength division multiplexer. The second light emitting units are arranged to correspond with the second wavelength division multiplexer.

Abstract: A multi-channel parallel optical communication module includes a casing having an airtight cavity, an optical communication assembly accommodated in the airtight cavity, and a temperature controller in thermal contact with the optical communication assembly. The optical communication assembly includes a plurality of optical communication units disposed at same level, and a number of the plurality of optical communication units is greater than four.

Abstract: An antenna apparatus comprises a semiconductor die in a molding compound layer, a first through via is between a sidewall of the semiconductor die and a sidewall of the molding compound layer and an antenna structure over the molding compound layer, wherein a first portion of the antenna structure is directly over a top surface of the semiconductor die and a second portion of the antenna structure is directly over a top surface of the first through via.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

Abstract: A device for evaluating the service life of a bearing includes an operating condition obtainment unit configured to obtain a current operating condition of the bearing, a first acquisition unit configured to acquire a current vibration signal of the bearing under the current operating condition, a computation unit configured to compute a current vibration value of the bearing, a spalling obtainment unit configured to obtain a current surface spalling area of the bearing corresponding to the current vibration value of the bearing and further configured to obtain a current spalling rate of the bearing under the current operating condition, and a replacement reminder unit configured to transmit a bearing replacement reminder information when the current surface spalling area of the bearing is detected to be greater than a predetermined first area.

Abstract: The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.

Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.